Folic Acid-adorned Nanomedicines for Targeted Chemotherapy

Stella Princeton*

Editorial Office, Medical Reports and Case Studies, France

Corresponding Author*
Stella Princeton
Editorial Office, Medical Reports and Case Studies, France
E-mail: healthprior@peerjournal.org

Received: 03-July-2023; Manuscript No. mrcs-23-98664; **Editor assigned:** 04-July-2023, Pre QC No. mrcs-23-98664 (PQ); **Reviewed:** 12-July-2023, QC No. mrcs-23-98664(Q); **Revised:** 18-July-2023, Manuscript No. mrcs-23-98664 (R); **Published:** 21 July-2023,doi:10.4172/2572-5130.8.03.1000250

Perspective

Chemotherapy is a widely used treatment for cancer, but it has several drawbacks, including its non-specific nature that often leads to serious side effects. The development of targeted drug delivery systems has been an active area of research for decades, with the goal of improving the efficacy and reducing the toxicity of chemotherapy. One promising approach is the use of folic acid-conjugated nanomedicines for targeted chemotherapy. Folic acid (FA) is a vitamin that is essential for cell growth and division. It is taken up by cells through the Folate Receptor (FR), a protein that is overexpressed in many types of cancer cells, including ovarian, breast, lung, and colorectal cancers. This characteristic makes FA an attractive targeting ligand for nanomedicines. Nanomedicines are drug delivery systems that consist of a nanoscale carrier, such as liposomes, dendrimers, or polymeric nanoparticles, that can encapsulate and transport drugs to the target site. By modifying the surface of the Nano-carrier with FA, the nanomedicine can selectively bind to FR-overexpressing cancer cells, leading to increased uptake of the drug and improved therapeutic efficacy.

Several studies have reported the development of folic acid-conjugated nanomedicines for targeted chemotherapy. For example, in a study by Lu, poly (ethylene glycol)-poly (lactic acid) (PEG-PLA) nanoparticles were decorated with FA and loaded with the chemotherapy drug paclitaxel. The FA-modified nanoparticles showed significantly higher uptake by FR-overexpressing cancer cells compared to non-targeted nanoparticles, resulting in enhanced cytotoxicity and apoptosis. In another study by Wang, a liposomal formulation of doxorubicin was conjugated with FA and tested in a mouse model of ovarian cancer. The FA-modified liposomes exhibited higher accumulation in the tumor tissue and lower distribution in healthy tissues compared to non-targeted liposomes. This led to improved tumor growth inhibition and reduced toxicity.

Furthermore, the use of folic acid-conjugated nanomedicines has shown promising results in the treatment of multidrug-resistant cancer. Multidrug resistance (MDR) is a major obstacle to the success of chemotherapy, and it often arises due to the overexpression of drug efflux pumps, such as P-glycoprotein (P-gp). These pumps can actively pump out chemotherapy drugs from cancer cells, reducing their effectiveness. By targeting FR-overexpressing cancer cells, folic acid-conjugated nanomedicines can bypass P-gp-mediated drug efflux and deliver the drug directly to the tumor site.

In a study by Zhou, FA-conjugated mesoporous silica nanoparticles were loaded with the chemotherapy drug docetaxel and tested in a cell line that overexpresses P-gp. The FA-modified nanoparticles showed significantly higher cellular uptake and cytotoxicity compared to non-targeted nanoparticles, and they were able to overcome MDR in vitro. Furthermore, in a mouse model of drug-resistant breast cancer, the FA-conjugated nanoparticles exhibited improved tumor growth inhibition and increased survival compared to non-targeted nanoparticles. Despite the promising results of folic acid-conjugated nanomedicines, there are still several challenges that need to be addressed. One major issue is the heterogeneity of FR expression in cancer cells. While FR is overexpressed in many types of cancer, not all cancer cells express it at the same level. This can lead to variability in the targeting efficiency of folic acid-conjugated nanomedicines and limit their efficacy.

Another challenge is the potential for off-target effects. While FA is generally considered safe, it is possible that the conjugation of FA to the nanomedicine could inadvertently lead to non-specific binding and uptake by normal cells that express low levels of FR. This could result in off-target effects and potential toxicity. Therefore, further studies are needed to optimize the design and dosage of folic acid-conjugated nanomedicines to minimize off-target effects and maximize their therapeutic benefits. Additionally, the stability and long-term safety of folic acid-conjugated nanomedicines need to be thoroughly evaluated. The nanoparticles must remain stable during storage and circulation in the body to ensure proper drug delivery to the target site. Moreover, the potential immunogenicity and clearance mechanisms of the nanomedicines should be investigated to ensure their long-term safety and minimize any adverse immune responses.

In conclusion, folic acid-adorned nanomedicines hold great promise for targeted chemotherapy. By exploiting the overexpression of folate receptors in cancer cells, these nanomedicines can enhance drug delivery to tumor sites, improve therapeutic efficacy, and reduce systemic toxicity. They also offer potential solutions for overcoming multidrug resistance, a major challenge in cancer treatment. However, further research is needed to address the remaining challenges and optimize the design, dosing, and safety of folic acid-conjugated nanomedicines. With continued advancements in nanotechnology and targeted drug delivery, these innovative approaches have the potential to revolutionize chemotherapy and significantly improve patient outcomes in the fight against cancer.

Cite this article: Princeton, S. Folic Acid-adorned Nanomedicines for Targeted Chemotherapy. Med Rep Case Stud. 2023, 08(04), 001